Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the success of pacritinib in the treatment of myelofibrosis (MF) in patients with a range of cytopenias. Dr Bose highlights results from the PERSIST-1, PERSIST-2 (NCT01773187; NCT02055781), and PAC203 (NCT03165734) trials, and further comments on the improvement in anemia and the high rates of transfusion independence observed. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Pacritinib for patients with MF across the cytopenic spectrum
Теги
Speaker: Prithviraj BoseInstitution: The University of Texas MD Anderson Cancer CenterEvent: SOHO 2023Format: InterviewSubject: MyelofibrosisSubject: Myeloproliferative NeoplasmsField: TreatmentField: Disease biologyField: Trial updatesField: PerspectivesMedicines: PacritinibMedicines: RuxolitinibTrial: PERSIST-1Trial: PERSIST-2Trial: PAC203NCT01773187NCT02055781NCT03165734anemiacytopeniaJAK inhibitorstransfusion independence
